Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823417 | 0.85 | MEN1 (0.39) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4669089 | 0.73 | POLB (0.35) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4823413 | 0.73 | KMT2A (0.36) | MAPTALDH1A1MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL4670894 | 0.72 | POLB (0.34) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4825679 | 0.70 | — | — | |
| SCHEMBL4670961 | 0.69 | MEN1 (0.32) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4824088 | 0.68 | MEN1 (0.39) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL27252118 | 0.66 | KMT2A (0.39) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL7865566 | 0.66 | MAPT (0.40) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL3817147 | 0.65 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757586-B1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | SERVIER LAB (FR) | 2008-12-03 | — | — | EP | disclosed |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | disclosed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | disclosed |
| EP-1757586-A1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | Les Laboratoires Servier (FR) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | CHRNA1, CHRM1, CHRNA9 | MAPT 4252/4885ALDH1A1 531/4885MEN1 3199/4885 |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | CHRM1, CHRM2, CHRM3 | MAPT 4634/4885ALDH1A1 747/4885MEN1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.